People · Operator
Named in public records as an officer, director or promoter · active 2022–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zephyr AI, Inc. | — | Biotechnology | Series D+ | $129.7M | $1.5B | 2023 |
| Altesa BioSciences, Inc. | — | Pharmaceuticals | Series C | $110.0M | $373.5M | 2022 |
| Curevo, Inc. | — | Pharmaceuticals | Series C | $110.0M | $293.0M | 2025 |
Moncef Slaoui at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Moncef Slaoui on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Murray | 1 | 7 |
| Ittai Harel | 1 | 6 |
| Sol Barer | 1 | 6 |
| David Morgan | 1 | 6 |
| Seth Rudnick | 1 | 5 |
| Tal Zaks | 1 | 3 |
| Brett Giroir | 1 | 3 |
| Mario Barro | 1 | 3 |
| Grant Verstandig | 1 | 3 |
| Giovanni Mariggi | 1 | 2 |
| Charles Petty | 1 | 2 |
| Jeff Sherman | 1 | 2 |
| Nicholas Williams | 1 | 2 |
| Rachael Brake | 1 | 1 |
| John Tiernan | 1 | 1 |
| John Clerici | 1 | 1 |
| Andrew Drechsler | 1 | 1 |
| Jon Edwards | 1 | 1 |
| Baeksik Bae | 1 | 1 |
| George Simeon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.